Treatment of systemic lupus erythematosus: new therapeutic options

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune inflammatory disease of unknown cause, with heterogeneity in its clinical presentation, as well as variability in its clinical course and prognosis. The current goal of treatment is to achieve disease remission or a state of low activity, and thereby improve the patient's quality of life. Biological therapy in lupus, unlike other entities, although it has not been fully established, in recent years it has burst onto the scene with important therapeutic novelties. This review aims to update the therapeutic tools for the treatment of SLE focusing on the new molecules that have achieved the objectives of their clinical trials.

Keywords: Anifrolumab; Belimumab; JAK; Lupus eritematoso sistémico; Lupus nephritis; Nefritis lúpica; Obinutzumab; Rituximab; Systemic lupus erythematosus; Voclosporin; Voclosporina.